Brirel 90 Tablet

About Brirel 90 Tablet

Brirel 90 comes as a tablet with 90 mg of Ticagrelor, from Opsonin Pharma Limited. This includes unstable angina, non-ST elevation myocardial infarction and ST elevation myocardial infarction.

There are 13 brands of Ticagrelor listed in Bangladesh. The lowest listed price is Belinta 60 mg Tablet at ৳ 35.00 per unit.

What is Brirel 90 Tablet?

Brirel 90 is a tablet from Opsonin Pharma Limited, with the generic name Ticagrelor. Brirel 90 is taken together with aspirin. Its active ingredient is Ticagrelor, which belongs to a group of medicines called anti-platelet drugs. Ask your doctor or pharmacist if you are unsure about it.

Uses of Brirel 90

This includes unstable angina, non-ST elevation myocardial infarction and ST elevation myocardial infarction. It is prescribed whether the patient is managed with medicines alone or with procedures such as percutaneous coronary intervention or coronary artery bypass grafting. Brirel 90 is used in adults to help prevent atherothrombotic events after an acute coronary syndrome. Your doctor will decide if it is suitable for you.

How to use Brirel 90

Take Brirel 90 exactly as the doctor prescribes. Swallow the tablet with water. Brirel 90 is taken by mouth. It can be taken with or without food. If you miss a dose, ask the doctor or pharmacist what to do; the product information advises taking only the next scheduled tablet and not doubling up. Do not stop or change the medicine on your own, because stopping can raise the risk of heart attack, stent thrombosis and death.

Side effects of Brirel 90

Common side effects that have been reported with Ticagrelor include shortness of breath, bleeding, headache, cough, dizziness, nausea, diarrhoea, back pain, fatigue, chest pain, low blood pressure, high blood pressure and atrial fibrillation. The doctor can advise whether you need review or a change in treatment. Because it affects platelets, bleeding is a particular concern. Tell your doctor if any side effect bothers you or does not go away. Contact your doctor if you notice anything unusual after taking it.

Safety and precautions

It is not for people with moderate to severe liver problems or with allergies to the ingredients. Brirel 90 increases the risk of bleeding, so tell the doctor about any bleeding problem, peptic ulcer or past bleeding in the brain. It is not recommended in pregnancy, and it should not be used while breastfeeding unless the doctor decides the benefits outweigh the risks. Ask your doctor first if any of these apply to you.

Frequently asked questions

Why is Brirel 90 prescribed?

This includes unstable angina, non-ST elevation myocardial infarction and ST elevation myocardial infarction. It is prescribed whether the patient is managed with medicines alone or with procedures such as percutaneous coronary intervention or coronary artery bypass grafting.

How is Brirel 90 used?

Take Brirel 90 exactly as the doctor prescribes. Swallow the tablet with water.

Can Brirel 90 cause side effects?

Common side effects that have been reported with Ticagrelor include shortness of breath, bleeding, headache, cough, dizziness, nausea, diarrhoea, back pain, fatigue, chest pain, low blood pressure, high blood pressure and atrial fibrillation. The doctor can advise whether you need review or a change in treatment.

Can I use Brirel 90 in pregnancy or while breastfeeding?

It is not for people with moderate to severe liver problems or with allergies to the ingredients. Brirel 90 increases the risk of bleeding, so tell the doctor about any bleeding problem, peptic ulcer or past bleeding in the brain.

Indications

Ticagrelor is indicated for the prevention of atherothrombotic events in adult patients with Acute Coronary Syndromes (unstable angina, non ST elevation Myocardial Infarction [NSTEMI] or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

Pharmacology

Ticagrelor is a selective adenosine diphosphate (ADP) receptor antagonist acting on the P2Y12 ADP-receptor that can prevent ADP-mediated platelet activation and aggregation. Ticagrelor reversibly interacts with the platelet P2Y12 ADP-receptor.Ticagrelor does not interact with the ADP binding site itself, but interacts with platelet P2Y12 ADP-receptor to prevent signal transduction.Thus it prevents platelet activation & aggregation.

Dosage & Administration

Ticagrelor treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily. Patients taking Ticagrelor should also take aspirin daily, unless specifically contraindicated. Following an initial dose of aspirin (usually 325 mg), Ticagrelor should be used with a maintenance dose of aspirin of 75-100 mg. Maintenance dose of Aspirin above 100 mg decreased the efficacy of Ticagrelor. So, maintenance dose of aspirin above 100 mg should be avoided.

A patient who misses a dose of Ticagrelor should take only one 90 mg tablet (the next dose) at its scheduled time. Patients treated with Clopidogrel can be directly switched to Ticagrelor if needed. Switching from prasugrel to ticagrelor has not been investigated.

Treatment is recommended for up to 12 months unless discontinuation of Ticagrelor is clinically indicated. Ticagrelor can be administered with or without food.

Interaction

CYP3A inhibitors: Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin).

CYP3A inducers: Avoid use with potent inducers of CYP3A (e.g., rifampin, dexamethasone, phenytoin,carbamazepine and phenobarbital).

Aspirin: Use of Ticagrelor with aspirin maintenance doses above 100 mg reduced the effectiveness ofTicagrelor.

Simvastatin, Lovastatin: Ticagrelor will result in higher serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4. Avoid simvastatin and lovastatin doses greater than 40 mg.

Digoxin: Because of inhibition of the P-glycoprotein transporter, monitor digoxin levels with initiation of or any change in ticagrelor therapy.

Other Concomitant Therapy: Ticagrelor can be administered with unfractionated or low-molecular-weight heparin, GPIIb/llla inhibitors, proton pump inhibitors, beta-blockers, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers.

Contraindications

Ticagrelor is contraindicated in case of-
  • Hypersensitivity to Ticagrelor or to any of the excipients
  • Active pathological bleeding (peptic ulcer)
  • History of intracranial haemorrhage
  • Moderate to severe hepatic impairment
  • Co-administration of Ticagrelor with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)

Side Effects

Dyspnea,bleeding,headache,cough,dizziness,nausea,atrial fibrillation, hypertension, non-cardiac chest pain, diarrhea, back pain, hypotension, fatigue, chest pain.

Pregnancy & Lactation

Pregnancy category C. There are no or limited amount of data from the use of Ticagrelor in pregnant women.Ticagrelor is not recommended during pregnancy.

Nursing mothers: Available pharmacodynamic/toxicological data in animals have shown excretion of Ticagrelor and its active metabolites in milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breastfeeding or to discontinue/abstain from ticagrelor therapy taking into account the benefit of breastfeeding for the child and the benefit of therapy for the women.

Precautions & Warnings

General Risk of Bleeding: Drugs that inhibit platelet function including Ticagrelor increase the risk of bleeding.

Concomitant Aspirin Maintenance Dose: Use of Ticagrelor with maintenance doses of aspirin above 100 mg decreased the effectiveness of Ticagrelor. Therefore, after the initial loading dose of aspirin (usually 325 mg), use Ticagrelor with a maintenance dose of aspirin of 75-100 mg.

Moderate Hepatic Impairment: Ticagrelor has not been studied in patients with moderate hepatic impairment.

Discontinuation of Ticagrelor: Discontinuation of Ticagrelor will increase the risk of myocardial infarction, stent thrombosis, and death.

Overdose Effects

There is currently no known antidote to reverse the effects ofTicagrelor and it is not expected to be dialysable.Treatment of overdose should follow local standard medical practice.The expected effect of excessive ticagrelor dosing is prolonged duration of bleeding risk associated with platelet inhibition. If bleeding occurs appropriate supportive measures should be taken.

Storage Conditions

Protect from light & moisture. Store below 25° C. Keep out of reach of children.

Alternative brands of Ticagrelor

Other brands with the same generic name, cheapest first.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.